alpha-aminopyridine has been researched along with Liver Dysfunction in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Greenberg, J; Healey, JH; Hsu, C; LaCreta, F; Lasseter, KC; Marbury, TC; Stacchiotti, S; Tap, WD; Xu, LA; Zahir, H | 1 |
| Ji, Y; Miller, M; Samant, TS; Yang, S | 1 |
| Chen, J; Cheng, Y; Feng, H; Wang, H; Xu, J; Zhong, Q; Zou, Z | 1 |
| Houwen, RHJ; Slae, M; van der Woerd, WL; Wilschanski, M | 1 |
| Bertolini, A; Bodewes, FAJA; Jonker, JW; van de Peppel, IP; Verkade, HJ | 1 |
| Csonka, D; Duval, V; Hazell, K; Kobalava, ZD; Lorenzo, S; Trandafir, L; Waldron, E | 1 |
| Gillen, M; Marbury, T; Martin, P; Millson, D; Oliver, S | 1 |
| Anderson, N; Borlak, J | 1 |
| Miller, RD | 1 |
| Powell-Jackson, P; Williams, R | 1 |
| Dent, JG; Graichen, ME; Leonard, TB; Neptun, DA; Popp, JA | 1 |
3 review(s) available for alpha-aminopyridine and Liver Dysfunction
| Article | Year |
|---|---|
Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis.
Topics: Aminophenols; Aminopyridines; Benzodioxoles; Body Mass Index; Chloride Channel Agonists; Cystic Fibrosis; Digestive System; Drug Combinations; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration; Intestinal Diseases; Liver Diseases; Probiotics; Quinolones; Treatment Outcome; Weight Gain | 2017 |
Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease.
Topics: Aftercare; Aminophenols; Aminopyridines; Benzodioxoles; Chloride Channel Agonists; Cholagogues and Choleretics; Cystic Fibrosis; Drug Combinations; Elasticity Imaging Techniques; Humans; Liver Diseases; Liver Transplantation; Quinolones; Ursodeoxycholic Acid | 2017 |
Recent developments with muscles relaxants and their antagonists.
Topics: Acidosis; Aminopyridines; Electric Stimulation; Humans; Hypothermia; Kidney Diseases; Liver Diseases; Neostigmine; Neuromuscular Blocking Agents; Neuromuscular Junction; Pancuronium; Peripheral Nerves; Respiration; Sensory Receptor Cells; Synaptic Transmission; Water-Electrolyte Balance | 1979 |
3 trial(s) available for alpha-aminopyridine and Liver Dysfunction
| Article | Year |
|---|---|
Pharmacokinetics of Ribociclib in Subjects With Hepatic Impairment.
Topics: Aminopyridines; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Female; Half-Life; Humans; Liver Diseases; Male; Metabolic Clearance Rate; Middle Aged; Patient Acuity; Purines | 2021 |
A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Agents; Case-Control Studies; Female; Humans; Liver Diseases; Male; Middle Aged; Morpholines; Severity of Illness Index; Young Adult | 2016 |
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Topics: Aminopyridines; Arthritis, Rheumatoid; Female; Humans; Kidney Diseases; Liver Diseases; Male; Middle Aged; Morpholines; Oxazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines | 2015 |
5 other study(ies) available for alpha-aminopyridine and Liver Dysfunction
| Article | Year |
|---|---|
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
Topics: Aminopyridines; Area Under Curve; Humans; Liver Diseases; Multiple Organ Failure; National Cancer Institute (U.S.); Neoplasms; Pyrroles; United States | 2022 |
Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice.
Topics: Aminopyridines; Animals; Anti-Inflammatory Agents; Bacterial Load; Benzamides; Cyclopropanes; Cytokines; Inflammation; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Sepsis; STAT3 Transcription Factor; Survival Analysis | 2017 |
Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aminopyridines; Analgesics; Bile Duct Diseases; Causality; Chemical and Drug Induced Liver Injury; Female; Germany; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pharmacovigilance; Virus Diseases; World Health Organization | 2011 |
Use of flupirtine maleate as an analgesic in patients with liver disease.
Topics: Adult; Aged; Aminopyridines; Analgesics; Female; Humans; Liver Diseases; Male; Middle Aged; Palliative Care | 1985 |
Effects of methapyrilene on rat hepatic xenobiotic metabolizing enzymes and liver morphology.
Topics: Alanine Transaminase; Aminopyridines; Animals; Bile Acids and Salts; Bile Ducts; Chemical and Drug Induced Liver Injury; Epoxide Hydrolases; gamma-Glutamyltransferase; Liver Diseases; Liver Function Tests; Male; Methapyrilene; Microsomes, Liver; Mixed Function Oxygenases; Necrosis; Rats; Rats, Inbred F344 | 1985 |